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Pattern of treatmentAbstract Background: Epidemiological proﬁle and treatment outcomes of Lung and pleural
malignancies vary among different geographical regions. The aim of the study is to analyze the
clinico-pathological proﬁle and pattern of treatment of lung and pleural cancers at the Radiation
Oncology department, NCI, Cairo University.
Materials and methods: A review of 804 clinical patient records with 770 pathologically/cytolog-
ically conﬁrmed patients from Jan 2008-December 2012 was performed. Patients were evaluated
(clinical, demographic and pathological proﬁles) in addition to the treatment adopted.
Results: Median age was 56 years with a male: female ratio of 4:1. Smoking was reported in 63%
of patients. Dyspnea and chest pain were the most presenting symptoms (53%). Among lung cancer
patients; 78% were NSCLC and 12% SCLC with mesothelioma comprising 10%. Among
NSCLCs, adenocarcinoma and large cell undifferentiated carcinoma were the commonest histolog-
ical subtype (72%). Among NSCLC, 58% cases were of stage IV while among SCLC 73% cases had
extensive stage disease. Chemotherapy was administered to 47% (55% vs. 67%, and 35% vs. 31%
among non-metastatic lung cancer, mesothelioma patients and metastatic lung cancer and mesothe-
lioma patients respectively). Distant metastases (brain 48%, bone 36%) were reported in 45% of
patients. The pattern of treatment intent was palliative (88%) vs. 12% treated with radical intent.
Conclusions: Advanced stages at presentation reﬂect the palliative pattern of treatment.
Hypo-fractionated radiotherapy for lung and pleura malignancies as a palliative measure isrculosis.
272 E.M. Khalil et al.the current practice. Implementation of early palliative care should be considered for metastatic
patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
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Lung cancer is the most lethal newly diagnosed cancer. Its high
mortality and low 5 years survival rates (<14%) pose a major
challenge in addition to the sharp rise in its incidence among
all age groups. The reported median age of lung cancer
patients is 65–70 years [1–4]. Untreated lung cancer patients
live on an average for 7 months [5].
Estimated new cancer cases of lung cancer is estimated to
be approximately 15% among males and 14% among females;
ranking second after prostate and breast for both genders;
while ranking ﬁrst for estimated new cancer deaths with a
31% and 26% death rates among males and females respec-
tively [6].
In Egypt, according to the Gharbia population based and
National Cancer Institute; Cairo University cancer registries
lung cancer ranks 5th and 7th among both genders with a
5% and 4% incidence respectively. Pleural malignancy consti-
tutes 1.4% ranking 16th [7,8].
Tobacco smoking (cigarette); the leading cause for lung
cancer, is responsible for about 83% and 90% of females
and males lung cancer, respectively. Passive-smokers are also
at increased risk of developing lung cancer [4]. Heavy smoking
(>20 cigarettes/day) has been shown to confer a risk of
between 15- and 25-fold relative to nonsmokers [9,10].
Lung cancer is pathologically classiﬁed into SCLC (15%)
and NSCLC types (>85%). Two thirds of NSCLC have
non-resectable disease on initial presentation and less than
one third of patients with SCLC have limited-stage disease at
presentation. Reported survival rates are commonly very poor
even in patients with non-metastatic disease [11–13].
Symptomatic lung cancer patients often presents in a
locally advanced or metastatic disease status [14]. Depending
on the stage of the disease, therapy is planned with treatment
intents either to palliate speciﬁc tumor-related symptoms (pain
medications/low dose radiotherapy) or local tumor control by
trimodality therapy or combinedchemoradiation [15].
Patients presenting with locally advanced or metastatic
lung cancer are best treated with palliative-intent radiotherapy
(RT); known to be effective in alleviating symptoms resulting
from intrathoracic disease, such as hemoptysis, cough, chest
pain, dyspnea, and airway obstruction. Short RT fractionation
schedules have been recommended by many guidelines [16–21].
The estimated prognosis after diagnosis of advanced disease
stage has been reported to be less than 1 year [22,23].
Brain metastasis is reported to be 30–60% among patients
diagnosed with lung cancers. Whole brain radiation therapy
(WBRT) alone was offered as ﬁrst-line therapy for the man-
agement of brain metastases with reported median survival
of 5–6 months [24,25].
Mesothelioma was described as an insidious neoplasm with
long latency period (up to 40 years) after exposure to asbestos.
Concomitant smoking enhances the risk of malignancy in an
asbestos worker, with a 60-fold increased risk of developingNSCLC.Males were three timesmore likely to be diagnosed than
females, and more than half of the patients presented with stage
III or stage IV disease [26]. Peak incidence occurs in the 5th and
6th decades of life. Surveillance Epidemiology and End Results
(SEER) registry data report approximately 3300 new cases annu-
ally, compared to nearly 200,000 cases of lung cancer [27].
Radiotherapy alleviating pain or reducing transient chest
wall masses; which has seldom demonstrated signiﬁcant
response as the primary modality for intrathoracic disease did
not improve survival [28]. The value ofRT in patients with unre-
sectable mesothelioma is controversial, with little evidence sup-
porting RT in the management of mesothelioma [29] Expected
median survival in patients treated with chemotherapy is
12 months; and approximately 17 months after administering
chemotherapy andRT after Extra Pleural Pneumonectomy [30].
Materials and methods
A retrospective review of lung and pleural cancer patients
(N= 804) from the database of the Department of Radiation
Oncology – NCI, Cairo University who were treated from Jan-
uary, 2008 through December, 2012; aiming to identify pattern
of treatment and analyze their clinical and epidemiological
characteristics was performed.
Parameters reviewed in the patients’ clinical records included
demographic data, presenting symptoms, complete history and
physical examination, routine laboratory results, histo-
cytopathological reports, and CT scan of the chest, abdomen,
and pelvis; in addition to the treatment adopted.After reviewing
patients’ records some data were missing due to limitations in
the context of the nature imposed by the retrospective study.
Most of the patients were treated as a free section with only
27% being referred from insurance hospitals for radiotherapy.
Brain CT/MRI was routinely done at our institution for
patients with neurological symptoms or signs. A histological
diagnosis of non-small/small cell lung carcinoma was required
for treatment unless metastatic disease was evident in the pres-
ence of a lung mass upon presentation in a patient with poor
performance; therein treatment was started on palliative basis
to control symptoms and sputum cytology was requested to
reach a diagnosis.
Most of the patients were treated by multidisciplinary
approach (free section patients) while those referred from Insur-
ance hospitals; mostly were referred for radiotherapy due to the
deﬁciency of Radiation therapy facility. Treatment protocols
included neoadjuvant chemotherapy followed by RT for medi-
cally ﬁt patients, while palliative chemotherapy and RT were
adopted for medically unﬁt or patients presented with extra tho-
racic metastases with poor performance (Appendix 1).
Non-metastatic lung cancer patients were treated by
chemo-radiotherapy. Radical RT implemented for curative
treatment of patients with un-resectable NSCLC was a
60 Gy total dose and fractionation of 1.8–2.0 Gy per fraction,
with one fraction per day, 5 days a week.
Table 1 Patient’s demographics.
Items No. (%)
Gender
Males 656 (81.6)
Females 148 (18.4)
Age (years) median (56 years)
640 49 (6.2)
40–60 386 (48.6)
>60 359 (45.2)
Region
Cairo 579 (72.0)
Upper Egypt 145 (18.0)
Lower Egypt 80 (10.0)
Occupation
Workers 112 (16.0)
Farmers 48 (6.0)
Employees 66 (8.1)
Driver 41 (5.0)
Carpenter 10 (1.2)
No occupation 405 (49.0)
Others 26 (3.2)
Symptoms
Cough 122 (15.2)
Dyspnea 189 (23.5)
Chest pain 215 (26.2)
Hemoptysis 81 (10.1)
Hoarseness of voice 7 (9.0)
Neurological manifestation 90 (11.2)
Bone pains 67 (8.3)
Superior Vena Cava obstruction 15 (1.9)
Family history
Yes 29 (3.6)
No 715 (89.0)
Smoking
Yes 477 (63.0)
No 281 (37.0)
Some clinical records were deﬁcient signiﬁcance is that if you add
the numbers it will not show the 100% of the studied population.
Figure 1 Frequency of cases over the studied 5 years.
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whole brain RT a dose of either 30 Gy in 10 fractions over
2 weeks or 20 Gy in 5 fractions over one week depending on
the performance status with the shorter regimen being adopted
for the poor performance ones.
Single fraction palliative radiotherapy to the bony
metastatic sites was the most commonly used fractionation
schedule followed by 20 Gy in four or ﬁve fractions in one
week treatment.
Mesothelioma patients were mainly treated with a palliative
intent (30 Gy/10 fractions in 2 weeks) as most patients
presented with advanced disease and were considered unre-
spectable with only 9 patients treated post-operatively. Sixteen
patients were treated with a radical dose of 50 Gy/25 fractions
in 5 weeks post upfront chemotherapy with stable disease
using mixed photon/electron two dimensional radiotherapy;
with lung shield and electron beam RT to the pleural surface
to avoid radiation pneumonitis.
Ethical consideration
To ensure privacy, dignity and integrity, names of the patient
were kept conﬁdential.
Statistical analysis
Data were collected, coded and entered to a computer before
being analyzed using the software, Statistical Package for
Social Science, (SPSS) version 19. Qualitative data were
presented as frequency distribution with its percentage, while
quantitative data were presented as means and standard
deviation. Comparisons of qualitative data were performed
using Chi-squared test while Student’s t-test was used to
compare quantitative data. ANOVA was done whenever
needed. P-values of <0.05 were considered the cut off point
for the level of signiﬁcance.
Results
Lung cancerwas prevalent amongmales (81.6%)with amale:fe-
male ratio of 4:1. Fifty-ﬁve percent of the studied patients were
<60 years of age and nearly two-thirds lived in urban areas.
Performance status (2) was prevalent (54%) among the
studied group compared to 26% with PS 3, 10% with PS 4
and only 10% were PS 1 (Appendix 1). Tobacco smoking
was reported in 63%. Most of them were married (98%).
Housewives and retired patients were reported to be 17%
and 29% respectively, while those with no occupation consti-
tuted 11%. Most of the cases were symptomatic, with 26%,
23.5%, 15%, and 11% complained of chest pain, dyspnea,
cough and neurological manifestations respectively. Superior
Vena Cava obstruction was present in 2% of lung cancer
patients. Pleural effusion was present in 28%. Hypertension
and diabetes were reported among 12% and 16% respectively.
Peak incidence was observed in the year 2012 (Table 1, Fig. 1).
Twenty-four lung cancer patients with Poor performance
Status (PS 3 and 4) were diagnosed and treated based on only
radiological ﬁndings of lung mass with brain and/or bone
metastases. In addition ten mesothelioma patients were diag-
nosed by radiological ﬁndings.
274 E.M. Khalil et al.Non-small cell lung carcinoma pathology was reported in
(79%) compared to 12% for small cell carcinoma pathology.
Only 6% of NSCLC underwent curative surgery. Regarding
radiation therapy treatment, most of the cases (88%) were
treated with a palliative intent compared to only (12%) for
whom radical radiotherapy was adopted. Radiotherapy to pri-
mary site with a radical intent was reported in 19%, 5% and
3% for NSCLC, SCLC and mesothelioma patients respectively
(Fig. 2).
The below Fig. 3 shows the yearly distribution of patholog-
ically proven referred cases for treatment in the radiotherapy
department which showed a statistical signiﬁcance between
the three types of pathology (p= 0.001).
Tables 2 and 3 showed statistical signiﬁcance difference
comparing disease pathology and disease status (localized/
metastatic) with chemotherapy treatment, smoking, gender,
age, occupation, and disease symptoms.
Chemotherapy was implemented in 55% and 67% among
the non-metastatic lung cancer and mesothelioma patients
respectively; while only 35% and 31% of metastatic lungFigure 2 Distribution of patients in relation to pa
Figure 3 Distribution of the studied popucancer and mesothelioma patients were treated by palliative
chemotherapy. Among the whole group of the studied patients
53% were not treated by chemotherapy compared to 47%
treated by chemotherapy.
Metastatic disease at presentation was reported in 45% of
patients; brain as the only site of metastases was reported
among 46% followed by bone only metastasis in 36% of the
treated patients (Table 4).
Discussion
Analysis of the clinico-pathological proﬁle of lung and pleura
cancer patients at our department as compared to Western
population revealed that median age (56 years) of our patients
was almost 10 years younger [31–33]; with most of the previous
Egyptian studies reporting a similar (5th decade) median age
[34–36]. Smoking is always attributed to lung cancer develop-
ment [37,38]. In this study, almost two/third of the patients
were smokers; most of which were cigarette smokers. Smoking
was prevalent mainly in the urban population.thology and pattern of Radiotherapy treatment.
lation according to disease pathology.
Table 2 Pathology versus patients characteristics.
Variable Pathology Total P-value
SCLC NSCLC Mesothelioma
Chemotherapy** No 35 329 36 400 0.021
Yes 54 276 40 370
Smoking No 13 206 66 285 0.001
Yes 76 399 10 485
Gender Female 12 99 31 142 0.001
Male 77 506 45 628
Age <40 5 27 15 47 0.001
41–60 41 270 56 367
>61 21 303 15 339
Governorate Giza, Cairo, Qalyoubia 58 409 49 516 0.002
Minia, Fayoum, Beni-Suef 11 101 12 124
Helwan 3 28 10 41
Delta 17 44 3 64
Assuit, Sohag, Qena, Aswan 0 12 2 14
Suiz, Ismailia 0 11 0 11
Occupation Workers 28 93 6 0.0001
Farmers 4 35 7
Retirement 17 165 13
Employees 8 39 12
Housewives 6 91 22
None 6 58 9
Driver 7 31 3
Carpenter 0 9 1
Others* 9 14 3
Symptoms Cough 21 83 13 0.0001
Dyspnea 11 140 21
Chest pain 22 149 32
Hemoptysis 1 75 2
Hoarseness of voice 2 4 0
Neurological manifestation 5 80 2
Bone pains 8 51 5
Superior Vena Cava 4 11 0
Obstruction
* Others: butcher, baker, plumber.
** Thirty-four patients were treated with palliative RT only.
Table 3 Relationship between disease status and smoking, gender, age group and chemotherapy.
Variable Diseases Total P-value
Lung cancer Mesothelioma Metastatic lung cancer Metastatic mesothelioma
Chemotherapy No 166 22 227 11 426 0.001
Yes 204 48 121 5 378
Smoking No 86 48 131 16 281 0.001
Yes 246 16 215 0 477
Gender Male 335 57 259 5 656 0.001
Female 35 24 71 18 148
Age <40 22 11 11 5 49 0.001
41–60 137 52 183 14 386
>61 206 17 132 4 359
Clinico-pathological proﬁle and pattern of treatment of lung and pleural cancers 275Advanced disease (stage IIIB–IV) at the time of presenta-
tion was (70% in NSCLC and 71% in SCLC); similar to others
from national and western series with almost 2/3 of patients of
NSCLC and of SCLC present in advanced stage [39–42].Although the use of palliative chemotherapy for NSCLC is
increasing, RT alone can provide more timely palliation of
thoracic symptoms without the morbidity of chemotherapy,
and may be the primary or only treatment option for
Table 4 Distribution of disease status among the studied
population.
Disease status Percentage (%)
Non-metastatic lung cancer 370 (51.6%)
Total metastatic lung cancer
 Metastatic LC to lungs
 Metastatic LC to brain
 Metastatic LC to bone
 Metastatic LC to liver
 Metastatic LC to bone and liver
348 (48.4%)
 30 (8.6)
 166 (47.7)
 124 (35.6)
 17 (5.0)
 11 (3.1)
Non-metastatic mesothelioma 70 (79.0%)
Total metastatic mesothelioma
 Metastatic mesothelioma to lungs
 Metastatic mesothelioma to brain
 Metastatic mesothelioma to bone
 Metastatic mesothelioma to liver
16 (21.0%)
 5 (31.0)
 2 (12.5)
 7 (44.0)
 2 (12.5)
Total 804 (100%)
276 E.M. Khalil et al.poor-PS patients, or patients who have declined or progressed
despite systemic therapy.
Analysis of the pattern of treatment in the current study
revealed that 53% of the studied patients were not treated
by chemotherapy (54% of NSCLC, 39% of SCLC and 47%
for mesothelioma) and only 35% and 31% of metastatic lung
cancer and mesothelioma patients were treated by palliative
chemotherapy. These ﬁgures are higher than those reported
(20–37%) in USA, Scotland and Australia (19–30% of
NSCLC and 20–25% of SCLC) and similar (43–50%) to
reports from Ireland, New Zealand and India [41,43–48]; fac-
tors that might be attributed for these differences were poor
PS, advanced disease stages and social reasons.
Radiotherapy in radical doses to the primary site with a
radical intent was adopted in only 19%, 5% and 3% of
NSCLC, SCLC and mesothelioma patients; ﬁndings that are
inferior to the reported ﬁgures (29–42% of NSCLC and 27–
36% of SCLC) received radical radiotherapy [11,49–50]. In
actual practice, 36–65% of non-metastatic cases actually
receive radiotherapy despite that guidelines recommend that
up to 76% of lung cancer patients should receive radiotherapy
during their treatment [51]. Palliative radiotherapy; the most
common type (88%) for local lung symptom control or for
brain and bone metastases adopted among the studied popula-
tion was in concordance with the internationally published
guidelines [17–21]. The marked underutilization radical radio-
therapy as a treatment modality may be explained by the still
practice of systemic chemotherapy for patients away from a
Radiotherapy facility. Outcome of these patients still remains
poor because of late presentation in advanced stage and poor
PS with many of them not amenable for radical, aggressive
treatment.
Conclusions
This 5-year analysis confers the predominance of late
advanced stages at presentation in addition to the high per-
centage of metastatic patients reﬂecting the palliative pattern
of treatment. Hypo-fractionated Radiotherapy for lung and
pleura malignancies as a palliative measure is the current
practice. National awareness campaigns are important to beimplemented in an effort to combat smoking (active/passive)
and to ensure industrial safety measures against asbestos and
chemical industrial aerosols as the only important preventive
measure. Early implementation of palliative care may lead to
signiﬁcant improvements in quality of life for patients with
poor prognosis.
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Appendix 1
Eastern Cooperative Oncologic Group (ECOG) performance
status.Grade Description0 Fully active, able to carry on all pre-disease performance
without restriction1 Restricted in physically strenuous activity but ambulatory
and able to carry out work of a light or sedentary nature,
e.g., light house work, oﬃce work2 Ambulatory and capable of all self care but unable to carry
out any work activities. Up and about more than 50% of
waking hours3 Capable of only limited self-care, conﬁned to bed or chair
more than 50% of waking hours4 Completely disabled. Cannot carry on any self-care.
Totally conﬁned to bed or chair5 DeadOken MM, Creech RH, Tormey DC, et al. (1982). ‘‘Toxicity
and response criteria of the Eastern Cooperative Oncology
Group”. Am. J. Clin. Oncol. 5 (6): 649–55.
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